Summit Therapeutics Inc. (SMMT) Earnings History
Annual and quarterly earnings data from 2003 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | -257.0% | -8467.0% | -11185.9% |
| 2021 | 100.0% | -4764.3% | -4897.8% |
Download Data
Export SMMT earnings history in CSV or JSON format
Free sign-in required to download data
Summit Therapeutics Inc. (SMMT) Earnings Overview
As of March 1, 2026, Summit Therapeutics Inc. (SMMT) reported trailing twelve-month net income of -$1.08B, reflecting -3.6% year-over-year growth. The company earned $-1.44 per diluted share over the past four quarters.
Looking at the long-term picture, SMMT's historical earnings data spans multiple years. The company achieved its highest annual net income of $10M in fiscal 2018.
Summit Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including BNTX (-$572M net income, -0.2% margin), MRNA (-$3.12B net income, -1.1% margin), PCVX (-$767M net income), SMMT has comparable earnings metrics. Compare SMMT vs BNTX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$1.08B | -387.8% | -$812M | $-1.44 | - | - |
| 2024 | -$221M | +64.0% | $313,000 | $-0.31 | - | - |
| 2023 | -$615M | -680.5% | -$90M | $-0.99 | - | - |
| 2022 | -$79M | +11.1% | -$60M | $-0.38 | -11185.9% | -8467.0% |
| 2021 | -$89M | -68.1% | -$86M | $-0.96 | -4897.8% | -4764.3% |
| 2020 | -$53M | -120.6% | -$53M | $-0.76 | -6127.6% | -6185.2% |
| 2019 | -$24M | -341.9% | -$23M | $-0.15 | -3903.4% | -3697.5% |
| 2018 | $10M | +134.6% | $5M | $0.11 | 17.5% | 9.6% |
| 2017 | -$29M | -33.5% | -$37M | $-0.15 | -163.1% | -209.0% |
| 2016 | -$21M | +12.2% | -$31M | $-0.43 | -742.0% | -1078.6% |
See SMMT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SMMT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SMMT vs AGIO
See how SMMT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SMMT growing earnings?
SMMT EPS of $-1.44 reflects slowing growth at -3.6%, below the 5-year CAGR of N/A. TTM net income is $-1.1B. Expansion rate has moderated.
What are SMMT's profit margins?
Summit Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SMMT's earnings?
SMMT earnings data spans 2003-2025. The current earnings trend is -3.6% YoY. Historical data enables comparison across business cycles.